British Business Bank Research
Investment Thesis
British Business Bank is the UK government's state-owned economic development bank, wholly owned by HM Government through the Department for Business and Trade. Its statutory mission is to drive sustainable growth and prosperity across the UK by improving access to finance for smaller and scaling businesses, and to support the transition to a net zero economy. Unlike a traditional VC, it operates as a fund-of-funds, co-investor, and (increasingly) direct equity investor, deploying public capital to fill gaps in the UK's private financing markets rather than optimizing purely for financial return.
Stage Focus
Coverage spans the full company lifecycle through different programmes: Start Up Loans for pre-seed founders, Regional Angels Programme and Nations and Regions Investment Funds for early-stage regional gaps, British Patient Capital and British Business Investments for venture and growth-stage fund commitments, and a fast-growing Direct Equity programme targeting late-stage, venture-backed scale-ups (typically Series C and beyond).
Check Size
Highly programme-dependent. The flagship Direct Equity strategy typically writes initial cheques of £10M-£40M, with long-term cumulative exposure to a single company of up to £75M. Fund commitments through British Patient Capital and Enterprise Capital Funds vary widely by vehicle. The Regional Angels Programme makes smaller co-investment commitments into angel-backed rounds outside London.
Lead Tendency
Mixed. Direct Equity investments are typically participations in large, syndicated late-stage rounds (e.g. alongside SoftBank Vision Fund 2, Microsoft, Nvidia in Wayve's round) rather than led rounds. Fund-of-funds activity (British Patient Capital, Enterprise Capital Funds) is inherently a limited-partner role, not a lead-investor role.
Recent Activity
The Bank has dramatically accelerated its Direct Equity programme: it more than doubled cumulative direct equity investment between October 2025 and June 2026, deploying more capital in nine months than in the prior four years combined. As of June 2026, the direct equity portfolio exceeds £600M across more than 50 companies, up from 31 in March 2025. Recent named investments include Wayve (£25M, self-driving AI, February 2026), Kraken Technologies (£25M, energy tech spin-out of Octopus Energy, January 2026), and Quantum Motion (£40M as part of a $160M Series C, May 2026). In June 2025 the government committed £6.6bn of new capital to the Bank as part of the UK's Modern Industrial Strategy, including a £4bn Industrial Strategy Growth Capital initiative and £2.6bn for Nations and Regions programmes. The Bank published a five-year strategic plan in November 2025 and launched the British Growth Partnership, a vehicle to channel pension fund capital into UK growth-stage companies, which announced partners and a targeted £200M first close the same month.
Portfolio Highlights
Direct equity portfolio companies span AI, deeptech, quantum computing, fintech, and clean energy: Quantexa (AI software; the Bank's first direct equity investment, 2020), Wayve (autonomous driving AI), Kraken Technologies (energy-sector SaaS), Quantum Motion and Oxford Quantum Circuits (quantum computing), 9fin (credit market data/fintech), and Elliptic (blockchain analytics and compliance). British Patient Capital separately has committed £2.287bn across 80 underlying VC funds, ten co-investments, and 18 Future Fund: Breakthrough deals.
Team
- Louis Taylor - Chief Executive Officer
- Leandros Kalisperas - Chief Investment Officer; joined January 2025 from West Yorkshire Pension Fund (where he was CIO managing ~£20bn); oversees the Bank's entire investment business including British Business Investments, British Patient Capital, Nations and Regions Investment Funds, and Enterprise Capital Funds
- Ian Connatty - Deputy Chief Investment Officer and Managing Partner, BBB Investment Services Limited (the Bank's FCA-regulated advisory/fundraising subsidiary); with the Bank and forerunner organizations since 2009
- Wyndham North - Managing Director, British Growth Partnership; leads the effort to bring pension fund capital into UK growth-stage investing
Decision Process
Institutional and multi-layered. Direct investment decisions run through an internal investment committee process within British Business Investments/British Patient Capital; the newly formed BBB Investment Services Limited is FCA-regulated for third-party fundraising (British Growth Partnership). Not a solo-GP or single-partner decision model.
Founder Preferences
The Direct Equity mandate explicitly targets fast-growing, venture-backed UK science and technology scale-ups in life sciences, deeptech (including advanced manufacturing), clean energy, defence, AI, and fintech that risk relocating or losing access to late-stage domestic capital. A stated policy goal is keeping high-growth UK companies from moving overseas or being acquired prematurely due to a shortage of domestic late-stage capital.
Geographic Focus
UK-wide, with an explicit mandate to address regional imbalances (Nations and Regions Investment Funds cover England, Wales, Scotland, and Northern Ireland; e.g. £130M Wales fund, £150M Scotland fund, £70M Northern Ireland fund). Headquartered in Sheffield, with a London office.
Organizational Structure
British Business Bank operates through several subsidiaries and programmes: British Business Investments, British Patient Capital, Start Up Loans Company, BBB Investment Services Limited (FCA-regulated), the Regional Angels Programme, Nations and Regions Investment Funds, Enterprise Capital Funds, the Life Sciences Investment Programme (£250M), and the newly launched British Growth Partnership. FY2024/25 results: £6.8bn of smaller-business financing supported, £226M revenue, £144M statutory profit before tax, and £4.9bn total assets.